Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial
Current therapies for type 1 diabetes mellitus (T1DM) rarely halt progressive β-cell function loss due to autoimmune attack. Human gingiva-derived mesenchymal stem cells (GMSCs) have been shown to have therapeutic effects on a variety of autoimmune diseases through their potent immunomodulatory capacity, but clinical e...